Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04678362 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

Study acronym: TALASUR
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv7
  2. Study completion date: Dec 2023 to Dec 2025v6
  3. Primary completion date changed from estimate of Jun 2023 to Jul 28, 2023v5
  4. Primary completion date: Jul 2022 to Jun 2023
    • Study sites: 12 to 14
    • Study completion date: Dec 2022 to Dec 2023
    • Eligibility criteria expanded, about 15 words
    v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2021 to Jun 1, 2021
    • Site details revised at 12 of 12 sites
    v3
  6. Study title shortened, about 5 wordsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objectif is to determine the efficacy of a maintenance treatment combining Talazoparib and Avelumab after platinum-based chemotherapy in patients with locally advanced/metastatic urothelial carcinoma.
Trial Details
NCT Number NCT04678362
Lead Sponsor Centre Francois Baclesse
Collaborators: Pfizer
Conditions
(from sponsor)		 Urothelial Carcinoma
Related terms Carcinoma, Transitional Cell
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov